All In Biotech

Drug Trial Radar · NCT05547464

Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers

A Phase Ib/IIa Two-part, Randomized, Placebo-controlled, Observer-blind, Dose-finding Evaluation Trial to Describe the Safety, Reactogenicity, and Immunogenicity of Two Investigational Vaccines Against Tuberculosis in BCG Vaccinated, HIV-negative Subjects

Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 497 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

497

Actual

Start

Jul 31, 2023

Primary completion

Mar 12, 2026

Study completion Jan 2027

Sponsor

Lead sponsor
BioNTech SEIndustry
Sponsor type
Industry
First posted
Sep 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a two-part randomized, placebo-controlled, observer-blind, safety and dose-finding Phase Ib/IIa study. This study will evaluate up to four dose levels of the BNT164 investigational vaccines (BNT164a1 and BNT164b1) to select a safe and tolerable dose in a three-dose schedule. This study includes: Part A (Phase Ib) and Part B (Phase IIa).

Conditions

  • Tuberculosis

Interventions

  • BNT164a1Biological

    Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection

  • BNT164b1Biological

    Multi-antigen RNA vaccine for active immunization against tuberculosis administered as intramuscular injection

  • PlaceboOther

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of solicited local reactions (pain, erythema/redness, induration/swelling) at the injection site up to 7 days after each doseTime frame: Up to 7 days after each dose
  2. Frequency of solicited systemic reactions (vomiting, diarrhea, headache, fatigue, muscle pain & joint pain, chills, and fever) up to 7 days after each doseTime frame: Up to 7 days after each dose
  3. Proportion of participants with at least one adverse event (AE) occurring from each dose to 28 days after each doseTime frame: From each dose up to 28 days after each dose
  4. Proportion of participants with at least one unsolicited AE occurring from Dose 1 to 28 days post-Dose 3Time frame: From Dose 1 up to 28 days post-Dose 3
  5. Proportion of participants with at least one serious AE or AE of special interest occurring from Dose 1 up to 168 days post-Dose 3Time frame: From Dose 1 up to 168 days post-Dose 3
  6. Number of unsolicited AEs from Dose 1 to 28 days post-Dose 3Time frame: From Dose 1 up to 28 days post-Dose 3

Locations

8 sites in 2 countries. Site status is shown where the registry gives one.

  • Centro de Investigação em Saúde de Manhiça (CISM) (recruiting participants for Part B only)

    Manhiça, Mozambique

  • Centro de Investigação e Treino em Saúde da Polana Caniço (CISPOC) (recruiting participants for Part B only)

    Maputo, Mozambique

  • CAPRISA eThekweni Clinical Research Site

    Berea, South Africa

  • South African Tuberculosis Vaccine Initiative SATVI

    Cape Town, South Africa

  • Centre for Lung Infection and Immunity UCT Lung Institute

    Cape Town, South Africa

  • Desmond Tutu Health Foundation - Masiphumele Research Office

    Cape Town, South Africa

  • Africa Health Research Institute (AHRI)

    Mtubatuba, South Africa

  • The Aurum Institute Tembisa CRC Clinic 4

    Tembisa, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.